Intuitive Surgical, Inc. (ISRG)

Over the past six months, Intuitive Surgical's stock has experienced some fluctuations. In Q4 2025, the company reported a 19% year-over-year revenue increase. In Q1 2026, Intuitive Surgical beat Wall Street estimates for profit and revenue. The da Vinci 5 received FDA clearance in 2024 and began its commercial rollout. In Q4 2025, Intuitive Surgical faced challenges in Asia, particularly in China. In Q4 2025, Ion system placements declined significantly. In March 2026, the company disclosed unauthorized access to part of its internal administrative network from a targeted phishing event.

The demand for Intuitive Surgical's products and services does not appear to be explicitly seasonal. The company's business model relies heavily on recurring revenue streams from instruments, accessories, and service contracts. Procedure volumes have shown consistent growth, indicating a relatively stable and increasing demand for its technology. The company's long-term value is tied to procedure volume, data, and software leverage, with recurring revenue making up a substantial majority of its total revenue.

Intuitive Surgical, Inc. specializes in robotic-assisted, minimally invasive care. The company's major products and services include da Vinci Surgical Systems, Ion Endoluminal System, Instruments and Accessories, Services and Training, and Digital Workflow and Analytics Tools. The da Vinci Surgical Systems enable surgeons to perform complex procedures with enhanced precision. The Ion Endoluminal System extends Intuitive's offerings into diagnostic endoluminal procedures. A significant portion of Intuitive's revenue comes from the sale of proprietary instruments and accessories. The company provides comprehensive customer service and support. Intuitive also offers integrated digital capabilities that provide connected offerings and program-enhancing insights for hospitals.

Intuitive Surgical has a significant global commercial footprint, with its products and services available in over 60 countries worldwide. The company's headquarters are in Sunnyvale, California, and it maintains significant U.S. operations in California and Georgia. Internationally, Intuitive Surgical has regional offices, training capabilities, and service infrastructure across Europe and Asia. The United States is Intuitive Surgical's largest market. Europe is a key growth region with increasing adoption of da Vinci systems, with Germany as a major revenue contributor. Asia-Pacific, including Japan, China, and South Korea, is a rapidly growing market, with Japan being a significant contributor. The company's global presence also extends to South America, the Middle East, and Africa.

Intuitive Surgical maintains a strong brand leadership and reputation for quality and precision within the robotic-assisted surgery market. The da Vinci surgical system is widely recognized as an industry standard. Increased competition in Asia has negatively impacted Intuitive's performance in the region. The significant decline in Ion system placements in Q4 2025 could raise questions about the growth trajectory of this newer product line. The disclosure in March 2026 of unauthorized access to part of its internal administrative network could be a concern for stakeholders regarding data security. Despite these challenges, Intuitive Surgical's overall reputation continues to solidify its market standing.

Intuitive Surgical, Inc. is a public company that is widely held with no single controlling shareholder. Institutional investors hold a significant portion of the company's stock. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp.